Skip to main content
Premium Trial:

Request an Annual Quote

UPMC Partners with Oracle, IBM, and Others on $100M Data Warehouse Effort

NEW YORK (GenomeWeb News) – Non-profit health system UPMC today announced a five-year $100 million investment to establish an enterprise analytics initiative to foster personalized medicine.

Pittsburgh-based UPMC is partnering with Oracle, IBM, Informatica, and dbMotion to create a "best-in-class" data warehouse that includes clinical, financial, administrative, genomic, and other information that is difficult to integrate and analyze, it said, adding that advanced analytic and predictive modeling applications are expected to result in better patient outcomes, improved research capabilities, and reduced costs.

With its partners, UPMC will install the necessary hardware and software to build a data warehouse that will include data from more than 200 sources of information across UPMC, UPMC Health Plan, and other entities such as laboratories and pharmacies, providing clinicians, researchers, and administrators secure, real-time access to data and analytic tools.

"UPMC, with the help of the Carnegie Mellon Software Engineering Institute, has methodically studied best practices in analytics both inside and outside of health care," Lisa Khorey, vice president of enterprise systems and data management at UPMC, said in a statement. "We're now ready to turn what we've learned into action to support our goal of developing new models of affordable, effective, patient-focused health care."

Terms of UPMC's agreements with its partners were not disclosed.

"UPMC's analytics initiative is one of the most ambitious and comprehensive efforts of its kind in health care," Neil de Crescenzo, senior vice president and general manager of Oracle Health Sciences, said. "Given the size, scope and influence of this leading academic medical center, the discoveries made here are likely to transform the practice of medicine far beyond the walls of UPMC."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.